Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...
This article describes the foundations of omaveloxolone approval in Friedreich ataxia (FA) and discusses future directions in FA treatment. Friedreich ataxia (FA), a rare autosomal recessive ...
The positive data from a phase 2 trial of omaveloxolone in neurodegenerative disorder Friedreich’s ataxia prompted a 34% increase in Reata’s share price after-hours, which added to earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback